Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$28.71M |
$2.48
+13.24%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$28.00M |
$11.71
-7.10%
|
|
RLYB
Rallybio Corporation
Core focus on rare diseases with lead and preclinical assets addressing complement dysregulation and iron overload.
|
$27.80M |
$0.67
-4.62%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$26.71M |
$3.84
-8.57%
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$26.60M |
$4.15
-5.68%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$26.53M |
$13.30
-2.67%
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$26.12M |
$2.21
+2.55%
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$26.07M |
$0.66
-1.51%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$24.92M |
$0.64
-3.56%
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$24.41M |
$2.28
+3.64%
|
|
XFOR
X4 Pharmaceuticals, Inc.
Company develops therapies targeting rare immune disorders (WHIM syndrome, CN), fitting Biotech - Rare Diseases.
|
$23.68M |
$4.08
+1.11%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$23.09M |
$1.05
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$22.96M |
$2.72
-2.51%
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$22.75M |
$7.32
-4.69%
|
|
COSM
Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
|
$22.31M |
$0.77
-4.41%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$21.52M |
$7.11
+0.28%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$21.26M |
$1.39
-3.82%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$21.19M |
$4.01
-1.47%
|
|
STCB
Starco Brands, Inc.
Vertical integration via acquisition of The Starco Group provides contract manufacturing capabilities.
|
$21.17M |
$0.03
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$20.81M |
$1.36
-5.86%
|
|
MGRX
Mangoceuticals, Inc.
Patented antiviral small-molecule therapeutics (MGX-0024) introduced as an IP asset with clinical development.
|
$20.52M |
$1.84
-11.30%
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$19.88M |
$1.70
+0.59%
|
|
ACUT
Accustem Sciences Inc.
Tests and technologies are oncology-focused biomarker diagnostics, placing ACUT in the oncology diagnostics space.
|
$19.45M |
$1.21
|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$18.49M |
$1.40
-1.76%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$18.26M |
$1.02
+0.49%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$18.21M |
$0.61
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$18.18M |
$3.79
-0.91%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$17.99M |
$2.35
-4.47%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$17.89M |
$0.43
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$17.82M |
$4.84
-1.72%
|
|
LPTX
Leap Therapeutics, Inc.
Leap Therapeutics is a biotech company focused on oncology therapies, with lead assets in antibody-based cancer treatments.
|
$17.36M |
$0.42
-6.98%
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$17.02M |
$1.01
-10.18%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$16.99M |
$1.92
-2.30%
|
|
NAII
Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
|
$16.87M |
$2.82
+3.49%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$16.53M |
$0.40
+1.04%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$16.30M |
$4.17
+0.48%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$16.13M |
$0.64
-5.33%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$15.64M |
$1.51
-4.11%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$15.58M |
$14.08
+0.79%
|
|
CRIS
Curis, Inc.
Curis's core business is oncology-focused biotech developing cancer therapies, anchored by emavusertib.
|
$15.48M |
$1.48
-1.01%
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$15.32M |
$0.07
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
LPCN
Lipocine Inc.
LPCN 1154 is targeted for postpartum depression, placing Lipocine's CNS/neuropsychiatric programs under Neuropsychiatric Drug Development.
|
$14.18M |
$2.62
-1.50%
|
Showing page 21 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
